Physician profile
Udo Igwe
NPI 1053954602
$1,366.04
in general payments reported to CMS, 2019-2025
17 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $230 · 2023: $115 · 2024: $654 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $279.11 | 2024-2025 | Rexulti |
| Abbvie INC. | $271.28 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $118.05 | 2024 | Farxiga |
| Neurocrine Biosciences, INC. | $114.48 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.58 | 2025 | Cobenfy |
| Janssen Products, LP | $102.30 | 2023 | Symtuza |
| Zealand Pharma US, INC. | $86.27 | 2022 | |
| Axsome Therapeutics, INC. | $60.95 | 2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $58.56 | 2024 | Gvoke Hypopen |
| Ani Pharmaceuticals, INC. | $33.42 | 2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $25.50 | 2024 | Rybelsus, Ozempic |
| Noven Therapeutics, LLC | $23.32 | 2024 | Xelstrym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.42 | 2024 | Jardiance |
| Lilly USA, LLC | $21.31 | 2024 | Jardiance |
| Amgen INC. | $17.25 | 2024 | Evenity, Prolia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $15.23 | 2024 | |
| Sanofi Pasteur INC. | $13.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udo Igwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.